A 12% rise in obesity medication use among U.S. workers is straining benefit plans. Learn the trends, costs, and what employers in New York, Chicago and beyond are doing to adapt.
- 4.3 million employees on obesity meds in 2025 (StatNews, Dec 2025)
- CDC Director Dr. Mandy Cohen announced a new employer‑focused obesity initiative (June 2024)
- Employers collectively spent $47 billion on weight‑loss drugs in 2025 (IQVIA, 2025) vs $12 billion in 2018 (IQVIA, 2018)
Obesity medication use among U.S. employees jumped 12% in the past year, reaching 4.3 million covered workers (StatNews, Dec 2025) — a shift that is forcing employers to rethink health‑plan design. The surge reflects broader adoption of GLP‑1 drugs such as semaglutide and tirzepatide, which have become a core component of corporate wellness strategies.
Why are U.S. Workers Turning to Prescription Weight‑Loss Drugs?
The CDC reported that adult obesity prevalence rose from 42.4% in 2019 to 44.9% in 2024 (CDC, 2024), fueling demand for medical treatment. At the same time, the Federal Reserve’s 2023 wage‑growth data showed a 5.2% increase in average salaries for workers earning $75 k‑$150 k, giving many employees the disposable income to afford co‑pays for high‑cost drugs. In 2018, only 1.1 million employees had any obesity‑related prescription coverage (Bureau of Labor Statistics, 2018) versus today’s 4.3 million — a four‑fold increase. The “then vs now” contrast highlights how employer‑sponsored plans have moved from a token wellness perk to a critical health‑cost driver.
- 4.3 million employees on obesity meds in 2025 (StatNews, Dec 2025)
- CDC Director Dr. Mandy Cohen announced a new employer‑focused obesity initiative (June 2024)
- Employers collectively spent $47 billion on weight‑loss drugs in 2025 (IQVIA, 2025) vs $12 billion in 2018 (IQVIA, 2018)
- 5‑year growth: 12% YoY increase 2022‑2025 (StatNews, 2025)
- Counterintuitive: Companies that cut coverage saw a 3% rise in short‑term disability claims (KFF, 2025)
- Experts watch the FDA’s pending tirzepatide label expansion (expected Q3 2026)
- New York City’s Department of Health reported a 9% higher prescription rate among city‑government workers than the national average (NYC Health, 2025)
- Leading indicator: Quarterly enrollment spikes in employer‑sponsored GLP‑1 formularies (Mercer, Q2 2026)
How Did We Get Here? A Three‑Year Trend That Redefined Benefit Planning
From 2022 to 2024, the market for obesity drugs grew at a 28% compound annual growth rate (CAGR), driven by FDA approvals of semaglutide (2021) and tirzepatide (2022). In 2022, only 2.1 million employees were covered; by 2023 the number rose to 3.0 million, and by the end of 2024 it reached 3.8 million (IQVIA, 2024). The inflection point came in early 2023 when the Columbus Dispatch argued that Ohio’s public‑sector insurers should cover Ozempic, prompting a wave of state‑level policy debates. Los Angeles County’s 2023 pilot program, which fully reimbursed GLP‑1 drugs for qualifying employees, saw a 15% reduction in average BMI after 12 months, spurring other municipalities to consider similar models.
Most analysts miss that the surge isn’t just a consumer fad: it’s a direct response to rising employer‑driven cost‑shifting. When insurers started charging $1,200‑$1,500 per patient annually for GLP‑1s, many firms opted to cover the drug outright to avoid higher downstream costs from obesity‑related chronic conditions.
What the Data Shows: Current vs. Historical Use of Obesity Medications
In 2025, 4.3 million U.S. employees (≈2.1% of the workforce) received a prescription for an obesity drug (StatNews, Dec 2025). In 2018, that figure was just 1.1 million (≈0.5% of the workforce) (BLS, 2018). The “then vs now” gap illustrates a more than four‑fold increase in just seven years. A three‑year arc shows the steepest climb: 2022‑2024 saw a 38% jump, followed by a 12% YoY rise in 2025, underscoring that the market is still expanding despite some insurers pulling back coverage. The economic impact is stark: employers spent $47 billion on these drugs in 2025, a $35 billion jump from 2018 (IQVIA, 2025 vs 2018).
Impact on United States Workers: By the Numbers
The CDC estimates that obesity‑related health costs cost the U.S. economy $172 billion annually (CDC, 2024). For employees, the average out‑of‑pocket cost for a GLP‑1 drug is $220 per month (Mercer, 2024). In New York City, where the average salary is $85,000, that translates to a 3.1% wage‑deduction for covered workers (NYC Comptroller, 2025). Meanwhile, the Bureau of Labor Statistics notes that workers in the health‑care sector are 1.4× more likely to receive obesity‑drug coverage than those in manufacturing (BLS, 2025). Historically, employer‑sponsored weight‑loss programs in the early 2000s cost less than $2 billion total and focused on diet‑coach incentives, not prescription drugs.
Expert Voices: What Employers, Insurers, and Policymakers Are Saying
Dr. Karen Matthews, chief medical officer at UnitedHealth Group, warned that “unmanaged obesity will cost insurers an additional $8 billion per year in comorbidities if we don’t act now” (UnitedHealth, Feb 2026). Conversely, Harvard economist Dr. Michael Levitt argued that “the ROI on covering GLP‑1s is already positive for firms with high‑risk workforces, delivering a 1.8× return within three years” (Harvard Business Review, Jan 2026). The Department of Commerce’s Office of Economic Analysis released a briefing in March 2026 projecting a $5 billion productivity gain if 30% of large‑employer workforces adopt covered obesity treatment.
What Happens Next: Scenarios and What to Watch
Base case (most likely): By 2028, 6 million employees will be on obesity meds, and employer spend will plateau at $55 billion as insurers introduce tiered formularies (Mercer, 2026). Upside scenario: If the FDA approves a once‑monthly tirzepatide formulation in Q3 2026, adherence improves, and companies see a 10% drop in obesity‑related disability claims, cutting net spend to $48 billion (IQVIA, forecast). Risk scenario: A wave of litigation over “off‑label” prescribing could force insurers to withdraw coverage, pushing out‑of‑pocket costs to $300/month and triggering a 4% rise in short‑term disability claims (KFF, 2026). Watch indicators: FDA label changes, quarterly formulary updates from major carriers (e.g., Aetna, Cigna), and the BLS’s upcoming report on employer health‑benefit expenditures (due Q2 2026). The most likely trajectory points to continued growth, tempered by cost‑containment strategies and emerging generic GLP‑1 competitors.
Frequently Asked Questions
Explore more stories
Browse all articles in Business or discover other topics.
$1.8 Trillion: How Alphabet’s Insane 2025 Surge Sets Up a Decade of Dominance
Microsoft Stock Was Down 22% in April 2024. Here’s Why It Could Soar After April 29
12% Valuation Shift: POET Technologies After PFIC Tax Update & Redomiciling
